Mutations in Three Genes Encoding Proteins Involved in Hair Shaft Formation Cause Uncombable Hair Syndrome

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.ajhg.2016.10.004

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
American Journal of Human Genetics

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Mutations in three genes encoding proteins involved in hair shaft formation cause uncombable hair syndrome

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>AJHG-D-16-00661R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>Mutations in three genes encoding proteins involved in hair shaft formation cause uncombable hair syndrome</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Article</td>
</tr>
<tr>
<td>Keywords:</td>
<td>uncombable hair syndrome, hair shaft disorder, PADI3, trichohyalin, TGM3</td>
</tr>
</tbody>
</table>
| Corresponding Author: | Regina Betz, M.D.  
                      | University of Bonn  
                      | Bonn, NRW GERMANY |
| First Author:      | Fitnat Buket Basmanav Uenal |
| Order of Authors:  | Fitnat Buket Basmanav Uenal  
                      | Laura Cau  
                      | Aylar Tafazzoli  
                      | Marie-Claire Mechin  
                      | Sabrina Wolf  
                      | Maria Teresa Romano  
                      | Frederic Valentin  
                      | Henning Wiegmann  
                      | Anne Huchenq  
                      | Rima Kandil  
                      | Natalia Garcia Bartels  
                      | Arzu Kilic  
                      | Susannah George  
                      | Damian J. Ralser  
                      | Stefan Bergner  
                      | David J.P. Ferguson  
                      | Ana-Maria Oprisoreanu  
                      | Maria Werner  
                      | Holger Thiele  
                      | Janine Altmueller  
                      | Peter Nuernberg  
                      | Daniel Swan  
                      | Darren Houniet  
                      | Aline Büchner  
                      | Lisa Weibel  
                      | Nicola Wagner  
                      | Ramon Grimalt  
                      | Anette Bygum |
Abstract: Uncombable hair syndrome (UHS), also known as "spun glass hair syndrome", "pili trianguli et canaliculi", or "cheveux incoiffables" is a rare anomaly of the hair shaft which occurs in children and improves with age. UHS is characterized by dry, frizzy, spangly and often fair hair that is resistant to being combed flat. Up to date both simplex and familial UHS cases with autosomal dominant as well as recessive inheritance have been reported. However, none of these cases were linked to a molecular genetic cause. Here, we report the identification of UHS causative mutations located in the three genes PADI3 (peptidylarginine deiminase 3), TGM3 (transglutaminase 3) and TCHH (trichohyalin) in a total of eleven children. All of these individuals carry homozygous or compound heterozygous mutations in one of these three genes, indicating an autosomal recessive inheritance pattern in the majority of UHS cases. The two enzymes PADI3 and TGM3, responsible for posttranslational protein modifications, and their target structural protein TCHH, are all involved in hair shaft formation. Elucidation of the molecular outcomes of the disease causing mutations by cell culture experiments and tridimensional protein models demonstrated clear differences in the structural organization and activity of mutant and wild type proteins. Scanning electron microscopy observations revealed morphological alterations in hair coat of Padi3 knockout mice. All together, these findings elucidate the molecular genetic causes of UHS and shed light on its pathophysiology, and hair physiology in general.
Mutations in three genes encoding proteins involved in hair shaft formation cause uncombable hair syndrome

Running head: Molecular genetics of uncombable hair syndrome

F. Buket Ü. Basmanav, Laura Cau, Aylar Tafazzoli, Marie-Claire Méchin, Sabrina Wolf, Maria Teresa Romano, Frederic Valentin, Henning Wiegmann, Anne Huchenq, Rima Kandil, Natalie Garcia Bartels, Arzu Kilic, Susannah George, Damian J. Ralser, Stefan Bergner, David J. P. Ferguson, Ana-Maria Oprisoreanu, Maria Wehner, Holger Thiele, Janine Altmüller, Peter Nürnberg, Daniel Swan, Darren Houniet, Aline Büchner, Lisa Weibel, Nicola Wagner, Ramon Grimalt, Anette Bygum, Guy Serre, Ulrike Blume-Peytavi, Eli Sprecher, Susanne Schoch, Vinzenz Oji, Henning Hamm, Paul Farrant, Michel Simon, Regina C. Betz

1 Institute of Human Genetics, University of Bonn, D-53127 Bonn, Germany
2 Department of Neuro- and Sensory Physiology, University Medical Center Göttingen, D-37073 Göttingen, Germany
3 CNRS UMR5165 and INSERM U1056 and University of Toulouse, F-31059 Toulouse, France
4 Department of Dermatology, University of Münster, D-48149 Münster, Germany
5 Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, D-10117, Germany
6 Balikesir University School of Medicine, Dermatology Department, TR-10100 Balikesir, Turkey
7 Dermatology Department, Brighton and Sussex University Hospitals NHS Trust, Brighton General Hospital, Elm Grove Brighton, BN2 3EW, UK
8 Nuffield Department of Clinical Laboratory Science, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
9 Department of Neuropathology and Department of Epileptology, University of Bonn, D-53127 Bonn, Germany
10 Cologne Center for Genomics, University of Cologne, D-50931 Cologne, Germany
11 Institute of Human Genetics, University of Cologne, D-50931 Cologne, Germany
12 Center for Molecular Medicine Cologne, University of Cologne, D-50931 Cologne, Germany
13 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, D-50931 Cologne, Germany
14 Computational Biology Group, Oxford Gene Technology, Oxford, OX5 1PF, UK
15 Pediatric Dermatology Department, University Children's Hospital Zurich, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
16 Clinical Center Darmstadt, D-64297 Darmstadt, Germany
17 Universitat Internacional de Catalunya, ES-08195 Sant Cugat del Vallès, Barcelona, Spain
18 Department of Dermatology and Allergy Centre, Odense University Hospital, DK-5000 Odense, Denmark
19 Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel
20 Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, D-97080 Würzburg, Germany
21 These authors contributed equally to this work.

*Correspondence should be addressed to R. C. B. (regina.betz@uni-bonn.de).
Abstract

Uncombable hair syndrome (UHS), also known as “spun glass hair syndrome”, “pili trianguli et canaliculi”, or “cheveux incoiffables” is a rare anomaly of the hair shaft which occurs in children and improves with age. UHS is characterized by dry, frizzy, spangle and often fair hair that is resistant to being combed flat. Up to date both sporadic simplex and familial UHS cases with autosomal dominant as well as recessive inheritance have been reported. However, none of these cases were linked to a molecular genetic cause. Here, we report the identification of UHS causative mutations located in the three genes PADI3 (peptidylarginine deiminase 3), TGM3 (transglutaminase 3) and TCHH (trichohyalin) in a total of eleven children. All of these individuals carry homozygous or compound heterozygous mutations in one of these three genes, indicating an autosomal recessive inheritance pattern in the majority of UHS cases. The two enzymes PADI3 and TGM3, responsible for posttranslational protein modifications, and their target structural protein TCHH, are all involved in hair shaft formation. Elucidation of the molecular outcomes of the disease causing mutations by cell culture experiments and tridimensional protein models demonstrated clear differences in the structural organization and activity of mutant and wild type proteins. Scanning electron microscopy observations revealed morphological alterations in hair coat of Padi3 knockout mice. All together, these findings elucidate the molecular genetic causes of UHS and shed light on its pathophysiology, and hair physiology in general.
Introduction

UHS [MIM 191480], was first described as a distinctive hair shaft defect in 1973.\textsuperscript{1} \textsuperscript{2} However, the phenotype had been recognized far earlier and had obtained notoriety as the famous literary character ‘Struwwelpeter-Shockheaded Peter’ from the children’s story published by the German physician Heinrich Hoffmann in 1845. This was later translated by Mark Twain to English as ‘Slovenly Peter’. Up to now about 100 isolated and syndromic UHS cases have been reported.\textsuperscript{3-5} Most of the cases are sporadic simplex occurrences but autosomal dominant or recessive inheritance patterns were also observed. In majority of the cases, UHS is an isolated condition of the hair, but it has occasionally been observed with additional symptoms, such as ectodermal dysplasias, retinopathia pigmentosa, juvenile cataract, and polydactyly.

Isolated UHS is characterized by silvery, blond or straw colored scalp hair that is dry, frizzy and wiry, has a characteristic sheen, stands away from the scalp in multiple directions and is impossible to comb. This hair shaft disorder occurs in children and improves with age. The hair growth rate can range from slow to normal. The clinical diagnosis of UHS can be confirmed by scanning electron microscopy (SEM) analysis of hair shafts.\textsuperscript{6-8} In at least 50% of the hair examined, this reveals a triangular or heart-shaped cross-section, in comparison to the normal circular cross section, as well as longitudinal grooves along the entire length of the hair shaft.\textsuperscript{9} The hair is not more fragile or brittle than normal hair. No effective therapy is yet available although biotin supplementation was reported to be successful in some cases.\textsuperscript{10}

Up to date no genetic alteration had been linked to UHS although familial occurrence has been well observed. In this study, we report UHS causative mutations in \textit{PADI3} [MIM 606755], \textit{TGM3} [MIM 600238] and \textit{TCHH} [MIM 190370], encoding for hair shaft proteins that display sequential interactions with each other. Overexpression of cells with constructs encoding for wild type (WT) and mutant
proteins in cell culture showed that the identified PADI3 and TGM3 mutations have profound effects on enzymatic activity of the respective proteins. The observation of alterations in whiskers and hair coat of Padi3 knockout mice confirms the essential role of this enzyme in hair shaft morphology. Altogether, our findings implicate that UHS occurs when interactions of a structural protein that gives shape and mechanical strength to the hair shaft are impaired by defects either in this protein itself or in others that mediate its interactions.

Materials and Methods

Study participants
Detailed information regarding the clinical descriptions of the individuals included in this study is given in the Supplemental Note: Case Reports. This study was performed according to the principles of the Declaration of Helsinki. Ethical approval was obtained from the ethics committee of the Medical Faculty of the University of Bonn and the participants provided written informed consent prior to blood sampling. Written informed consents of the affected individuals or their legal guardians were obtained for the publication of the case photos included in this manuscript.

Scanning electron microscopy
Hair shafts from various individuals with UHS and controls were mounted on stubs and sputter coated with either gold or platinum prior to examination in either a FEI Quanta FEG250 or a Philips 505 scanning electron microscope.

Exome sequencing
Exome sequencing was performed in two different centers. The two affected siblings of the discovery family from UK were exome sequenced by Oxford Gene Technology’s Genefficiency Sequencing Service. Genomic DNA (2 μg) was fragmented and enriched for human exonic sequences using the Human All Exon V5
Agilent Sure Select kit (Agilent Technologies) using the manufacturer’s protocol, and sequenced on the Illumina HiSeq 2000 platform using Truseq (v3 Chemistry) (Illumina) to generate 100 base paired-end reads. Fastq files were mapped to the reference human genome (hg19/GRCh37) using the Burrows-Wheeler Aligner (BWA) package (v0.6.2).\(^{11}\) Local realignment of the mapped reads around potential insertion/deletion (indel) sites was carried with the Genome Analysis Tool Kit (GATK) v1.6.\(^{12}\) Duplicate reads were marked using Picard v1.8 and BAM files were sorted and indexed with SAM tools v0.1.18.\(^{13}\) Approximately 12 and 14 GB of sequence data was generated for these samples and a minimum of 90.83% and 80.54% of the targeted exome was covered to a depth of at least 20× and 30× coverage, respectively. We filtered the variants for high-quality homozygous or potentially compound heterozygous, novel variants [defined against dbSNP 132 inclusion] that are shared by both siblings and are deleterious based on either of the SIFT, Polyphen and Condel predictions.

The affected individuals from Germany and Turkey were exome sequenced at the Cologne Center for Genomics. For whole-exome sequencing, 1 μg of genomic DNA was fragmented with sonication technology (Bioruptor, Diagenode). The fragments were end-repaired and adaptor-ligated, including incorporation of sample index barcodes. After size selection, a pool of all 5 libraries was subjected to an enrichment process with the SeqCap EZ Human Exome Library version 2.0 kit (Roche NimbleGen). The final libraries were sequenced on an Illumina HiSeq 2000 sequencing instrument (Illumina) with a paired-end 2× 100 bp protocol. Primary data were filtered according to signal purity by the Illumina Realtime Analysis (RTA) software v1.8. Subsequently, the reads were mapped to the human genome reference build hg19 using the BWA-aln alignment algorithm.\(^{11}\) GATK v.1.6 was used to mark duplicated reads, to do a local realignment around short insertions and
deletions, to recalibrate the base quality scores and to call SNPs and short Indels. For the Turkish individual this resulted in 7.5 Gb of unique mapped sequences, a mean coverage of 94 and 30x coverage of 91% of the target sequences. For the German individual, this resulted in 8.1 Gb of unique mapped sequences, a mean coverage of 106 and 30x coverage of 92% of the target sequences. The Varbank pipeline v.2.10 and interface developed in-house at the Cologne Center for Genomics were used for data analysis and filtering (unpublished data, H.T., J.A., and P.N.). The GATK UnifiedGenotyper variation calls were filtered for high-quality (DP>15; AF>0.25 + VQSLOD >-8 if possible, otherwise: QD>2; MQ>40; FS<60; MQRankSum>-12.5; ReadPosRankSum>-8; HaplotypeScore <13) rare (MAF ≤ 0.005 based on 1000 genomes build 20110521 and EVS build ESP6500) variants, predicted to modify a protein sequence or to impair splicing, in homozygous or compound heterozygous state.

**Sanger Sequencing**

Amplicons were generated under standard polymerase chain reaction conditions by using primers presented in Tables S1-S3. Sanger sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems) and an ABI 3100 genetic analyzer (Applied Biosystems). The data were analyzed using SeqMan II software (DNASTAR).

**Molecular cloning and mammalian cell cultures**

To construct the expression vectors for PADI3 and TGM3, the coding sequences (cDNA) of PADI3 (1995 bp) and TGM3 (2082 bp), were amplified from hair follicle cDNA, and cloned into the TOPO cloning site of pcDNA 3.1/V5-His-TOPO vector (Invitrogen) according to manufacturer’s protocol. The mutant constructs (PADI3: c.335T>A [p.Leu112His], c.881C>T [p.Ala294Val], c.1813C>A [p.Pro605Thr] and TGM3: c.1351C>T [p.Glu451Gln]) were generated by targeted mutagenesis using...
QuickChange II Site-Directed Mutagenesis kit (Agilent Technologies) according to manufacturer’s instructions. The constructs were verified by Sanger sequencing. The primers used for cloning and mutagenesis are listed in Table S4. The HaCaT human keratinocyte cell line was established by Boukamp et al. (1988). The HEK293T cell line was a kind gift from Thomas Zillinger (Institute of Clinical Chemistry and Clinical Pharmacology, University of Bonn). Both HaCaT and HEK293T cell lines were tested for mycoplasma contamination and confirmed to be mycoplasma free. Cells were maintained at 37°C (5% CO₂) in DMEM (Lonza) supplemented with 10% FCS (Life Technologies), 1% Penicillin-streptomycin (10,000 U ml⁻¹, Life Technologies) and 1% Amphotericin B (250 µg ml⁻¹, Life Technologies). Cells were cultured in 10 cm Petri dishes and on coverslips in 24-well plates for western blotting and immunofluorescence analysis, respectively. Transfections were carried on using the Lipofectamine3000 Transfection Kit (Life Technologies) according to manufacturer’s instructions. For each 10 cm plate, the following amounts of reagents were used: 15 µg plasmid, 1500 µl Opti-MEM (Life Technologies), 22.5 µl Lipofectamine3000 and 30 µl P3000 reagent. For each well in a 24-well plate, 0.5 µg of plasmid, 50 µl Opti-MEM, 1.5 µl Lipofectamine3000 and 1 µl P3000 reagent were used. Cells were harvested 48 h post-transfection.

**Topological tridimensional models of PADI3**

We constructed, as we had previously published, a topological tridimensional model of WT PADI3 using the crystal atomic coordinates of calcium-bound human PADI4 (Protein Data Bank accession number 1WDA). On this basis, topological models of the tridimensional structure of the three mutated enzymes were produced after *in silico* substitutions of the respective amino acids. All the models were refined by energy minimization (3x3000 iterations) using the MSI insight II modules Biopolymer, CHARMM and Viewer on an O2 SGI station. Energetic potentials after minimization
were all improved and validated. The three models were then validated by analyses of “Anolea data” and Ramachandran plots produced using the Swiss model expasy structure assessment tools and the Swiss-Pdb viewer software version 4.04, respectively. Finally, topological models of mutated PADI3 were individually compared to that of WT PADI3 after a magic fit on Swiss-Pdb viewer. Solid ribbon representations were displayed to show overviews of the tridimensional structures or enlargements focused on either the catalytic sites or the five calcium binding sites.

**Immunoblotting of HaCaT and HEK293T cell extracts**

Cells were collected in ice-cold PBS and centrifuged at 150 x g at 4°C for 10 min. The cell pellets were re-suspended in 40 µl of 10x RIPA buffer (Cell Signaling Technology) and 360 µl Protease Inhibitor Cocktail (Roche), incubated on ice for 15 min and sonicated 10 times for 10 sec, with 10 sec breaks on ice. After centrifugation at 10,500 x g for 10 min at 4°C, the supernatants were transferred to clean tubes and purified with Micro Bio-Spin Columns (Bio-Rad Laboratories) according to manufacturer's instructions. Purified lysates were mixed with 4x Laemmli sample buffer (Bio-Rad Laboratories) diluted in β-mercaptoethanol. After protein separation on TGX stain-free gels 4-15% (Bio-Rad Laboratories), the proteins were transferred on PVDF membrane (Amersham Biosciences). Western blotting was carried out using the WesternBreeze chemiluminescent kit (Invitrogen) according to manufacturer's instructions. The following primary antibodies were used with an incubation duration of 1h: mouse monoclonal anti-V5 (1:5000, V8012, Sigma Aldrich) and rabbit monoclonal anti-PADI3 / PAD3 (1:400, ab172959, Abcam) for PADI3 detection, mouse monoclonal anti-Flag (1:5000, F1804, Sigma Aldrich) and rabbit polyclonal anti TGM3-C-terminal (1:250, OAAB12971, Aviva Systems Biology) for TGM3 detection. Membranes were developed using the ChemiDoc MP imager (Bio Rad) for a maximum of 20 min. Data in Figure 4A are representative of western
blotting experiments from three independent transfections of HaCaT cells with *PADI3* constructs. Data in Figure 7A and Figure S7 emerge from six independent transfections of HaCaT (1x) and HEK293T (5x) cells with *TGM3* constructs. The relative quantities of WT and mutated TGM3 were assessed using Stain-Free technology that is based on total protein normalization (Bio-Rad Laboratories).\(^\text{17}\)

**Immunofluorescence analysis in HaCaT and HEK293T cells**

Transiently transfected HaCaT and HEK293T cells grown on coverslips were washed with 1x PBS for 5 min, permeabilized for 10 min with 1% Triton X-100 and blocked for 1h in PBS containing 1% bovine serum albumin, 10% normal goat serum and 0.1% Triton X-100. The cells were incubated with mouse monoclonal anti-V5 primary antibody (1:100, V8012, Sigma Aldrich) or mouse monoclonal anti-Flag antibody (1:500, F1804, Sigma Aldrich) for PADI3 and TGM3, respectively, for 3h at RT (or overnight at 4°C) and goat anti-mouse-cy3 secondary antibody (1:500, A10521, Life Technologies) with DAPI (D9542, Sigma Aldrich) for 40 min. The mounting was performed with Mowiol 4-88 (Roth). Images were captured with 63x or 10x oil immersion objectives using a Zeiss Axioplan 2 imaging microscope and the Cytovision 7.4 software. ImageJ was used for the analyses by applying the same brightness and contrast thresholds to all data. Data presented in Figure 4B and Figure 7B are representative of analyses from four independent transfections of HaCaT cells with *PADI3* constructs and five independent transfections of HaCaT (3x) and HEK293T (2x) cells with *TGM3* constructs, respectively. Two to three coverslips were analyzed per construct at each transfection.

**Activity of PADI3 in HaCaT cells**

Transiently transfected HaCaT cells grown on coverslips were air-dried. For indirect immunofluorescence, the cells were rehydrated for 15 min in PBS and permeabilized for 10 min in PBS containing 1% Triton X-100, and then non-specific binding sites
were blocked with PBS containing 2% fetal bovine serum and 1% Triton X-100. Slides were incubated with the following primary antibodies: mouse monoclonal anti-V5 (1:100, R960-25, Thermo Fisher Scientific) and ACPA antibodies (6 µg ml\(^{-1}\)) purified from a pool of rheumatoid arthritis [MIM 180300] patient sera.\(^{18; 19}\) Sera were from informed and consenting individuals attending the Rheumatology Center of Toulouse and have been declared to and approved by the Comité de Protection des Personnes Sud Ouest et Outre-Mer II (Toulouse, France). After incubation with the corresponding secondary antibodies, Alexa Fluor 488 Donkey anti-mouse IgG (1:10000, A21202, Thermo Fisher Scientific), Alexa Fluor 555 Goat Anti-human IgG (H+L) (1:10000, A21433, Thermo Fisher Scientific), and DAPI (D9542, Sigma-Aldrich), slides were mounted in Mowiol 4-88 (Calbiochem Merck Millipore). Images were captured with 20x dry or 63x oil immersion objectives using a Zeiss apotome microscope (Carl Zeiss). ImageJ was used for the analyses by applying the same brightness and contrast thresholds to all data. Data presented in Figure 5A are representative of analyses from two independent transfections of HaCaT cells with three coverslips for each single PADI3 construct.

**Activity of PADI3 produced in Escherichia coli**

*E. coli* strain BL21(DE3)-pLysS (Life Technologies) were transformed with 5 ng of the recombinant expression plasmids (pcDNA3.1/V5-His-TOPO–PADI3-WT, pcDNA3.1/V5-His-TOPO–PADI3-p.Leu112His, pcDNA3.1/V5-His-TOPO–PADI3-p.Arg294Thr–p.Arg294Val and pcDNA3.1/V5-His-TOPO–PADI3-p.Pro605Thr) and grown at 37°C overnight on agar-Luria Broth plates (MP Biomedicals) supplemented with ampicillin (50 µg ml\(^{-1}\)) and chloramphenicol (34 µg ml\(^{-1}\)). Four clones were selected for each plasmid. After selection, the bacterial clones were grown in Luria Broth medium supplemented with ampicillin (50 µg ml\(^{-1}\)), at 37°C for 3 hours and then overnight at 30°C. Harvested bacteria were sonicated 4x8 seconds (6~10W) on ice in
a Tris-HCl pH 7.6 buffer containing a cocktail of bacterial protease inhibitors (Sigma Aldrich). After centrifugation at 9,000 x g for 10 min, soluble proteins were recovered in the supernatants (clarified extracts).

To measure an in vitro deimination activity, the clarified extracts were incubated at 37°C in 100 mM Tris-HCl pH 7.6 buffer containing 10 mM CaCl2 and 5 mM DTT, for either 2 hours or overnight, under agitation at 1400 rpm. The deimination reactions were stopped by boiling for 3 min in Laemmli’s sample buffer. The proteins were then separated by SDS-polyacrylamide (10%) gel electrophoresis and immunodetected with the V5 Epitope Tag monoclonal antibody (1:5000, R960-25, Thermo Fisher Scientific) and the anti-modified citrulline antibodies. The blots were developed using the ECL prime™ system (GE Healthcare) as described by the manufacturer. Immunoblotting signals were recorded using a G:Box™ Chemi XT4 imager and GeneTool analysis software (Syngene) for a maximum of 20 min.

After one bacteria transformation, two independent clones for p.Leu112His, three for p.Pro605Thr and four for WT and p.Ala294Val were analyzed, with identical results; only those corresponding to two clones are illustrated. Data are representative of two technical replicates. The V5-antibody detections of recombinant PADI3 were confirmed using an anti-PADI3 antibody.

**Padi3-deficient mice**

All experiments with animals were approved by a local ethic committee (INSERM US006 CEEA-122) and carried out according to our Institution guidelines and EU legislation. *Padi3*-deficient mice (B6NCrl;B6N-A^{tm1Brd}Padi3^{tm1a(KOMP)Wtsi}/Or, abbreviated to *Padi3^{tm1a}* ) were generated by the Phenomin Program at the ICS Laboratory (Strasbourg, France). A promoter-less LacZ-reporter cassette containing a neomycin-resistance gene and flanked by two flippase recognition target sites was inserted between exons 4 and 5 of the *Padi3* gene, with loxP sites flanking the exons.
5 and 6. See http://www.mousephenotype.org/data/search/gene?kw=padi3 for more details. Mice were maintained in the TAAM animal facility (CNRS UPS44, Orléans, France) under pathogen-free conditions. They were killed by cervical dislocation. All efforts were made to minimize suffering. The following oligonucleotides were used for genotyping: Padi3 forward (5′-CTTTATTGATAAACACAGGAGGC-3′), Padi3 reverse (5′-CAATGGAATCCCTGTCCCTCACC-3′), and LacZ reverse (5′-CCAACAGCTTCCCACAACGG-3′). A wild type PCR product of 241 bp and a tm1a allele product of 365 bp were produced. Genotyping was confirmed using the Padi3 forward (5′-CCCTCTTGGAGGACCACAGGCTTATC-3′) and reverse (5′-GCACTCAAGAAGCAGAGGC-3′) primers, a wild type PCR product of 369 bp and a tm1a allele product of 421 bp were produced. No randomization was used. The SEM observations of whiskers and hair coat were done in blind, by two independent scientists.

Transglutaminase activity of TGM3

In order to compare the enzymatic activity of WT and mutant TGM3 in cell extracts of transiently transfected HEK293T cells we adapted the transglutaminase assay described by Aufenvenne et al. (2009). This assay is based on the incorporation of monodansylcadaverine into casein by transglutaminase, which causes an augmentation of fluorescence and an emission wavelength shift. Lysates of cells transiently transfected with WT or mutant TGM3 constructs were prepared 48 h post-transfection as described in the immunoblotting section. Lysates of mock-transfected cells were used as a negative control. The overexpression-translation of the target proteins was always confirmed by immunoblotting. For the assay, the lysates were incubated for 15 min in pre-warmed assay buffer (50 mM Tris/HCl, 10 mM CaCl2, 10 mM reduced glutathione, 2.5% glycerol, 2.5% DMSO, 25 µM monodansylcadaverine, 20 mM N,N-dimethylcasein, pH 8) at 37°C. Measurements were then made for 10
min at 37°C using a LS55 fluorescence spectrometer (Perkin Elmer) with excitation and emission wavelengths of 332 nm and 500 nm, respectively, and a 5.0 nm slit. The linear slopes of the measurements from technical triplicates of samples emerging from five independent transfections were used as a measure of the transglutaminase activity. The activity data were not normally distributed ($P < 0.050$, Shapiro-Wilk) and analyzed by a Kruskal-Wallis test (One Way ANOVE on Ranks) with post hoc Dunn's pairwise multiple comparisons test.

**Results**

**Identification of mutations in \textit{PADI3}, \textit{TGM3} and \textit{TCHH}**

In this study, we identified UHS causative mutations in three functionally related genes in a total of 11 individuals/families (Figure 1, Table 1 and Supplemental Note: Case Reports). The first family originated from the U.K. and had two affected and two unaffected siblings. The affected individuals reported typical hair problems in childhood with improvement while growing older (Figure 1J); gross and scanning electron microscopy observations were in line with an UHS phenotype (Figure 1K-L).

In order to elucidate the genetic background of UHS in this family, we performed whole exome sequencing (WES) in both of the affected siblings. We filtered the data for novel and deleterious homozygous or potentially compound heterozygous variants that are shared by the siblings and identified a homozygous missense variant c.881C>T (p.Ala294Val) within \textit{PADI3} (GenBank: NM_016233.2). The mutation co-segregated with the disease phenotype in the family (Figure 2A, Figure S1).

Then, we Sanger sequenced \textit{PADI3} in seventeen additional sporadic cases and detected the above mentioned mutation as well as two other recurrent missense mutations, c.335T>A (p.Leu112His) and c.1813C>A (p.Pro605Thr), in seven other
individuals/families\textsuperscript{24,25} (Table 1, Figure 2B-C, and Figure S2). We also identified an individual who carries the discovery mutation c.881C>T (p.Ala294Val) and a nonsense mutation, c.1732A>T (p.Lys578*), that occurred only once in our UHS cohort (Table 1, Figure 2B-C and Figure S2). These mutations were observed either in homozygous state or in compound heterozygosity as confirmed by parental DNA sequencing in three of the families (Figure S1). The allele frequencies of the \textit{PADI3} substitutions from Exome Aggregation Consortium (ExAC) data are presented in Table S5. The nonsense mutation was not observed in ExAC.

As a next step, we performed WES in four further UHS cases with no \textit{PADI3} mutations. We identified the nonsense mutation c.1351C>T (p.Gln451*) in \textit{TGM3} (GenBank: NM_003245.3) in a Turkish individual\textsuperscript{26} and the nonsense mutation c.991C>T (p.Gln331*) in \textit{TCHH} (GenBank: NM_007113.3) in a German individual (Figure 2D-G; Table S5). No homozygous loss of function mutations were observed in \textit{TGM3} or \textit{TCHH} in \textasciitilde60,000 sequenced individuals of the ExAC database.

\textbf{PADI3, TGM3 and TCHH interplay in hair shaft formation}

\textit{PADI3}, a gene of the \textit{PADI} family (\textit{PADI1-4} and \textit{6}), encodes the 664-amino acid peptidylarginine deiminase type III (Enzyme Commission number, EC.3.5.3.15).\textsuperscript{27} This posttranslational modification enzyme converts positively charged L-arginine residues of proteins into neutral citrulline residues in the presence of calcium ions. The process is called deimination or citrullination. \textit{PADI3} is mainly detected in skin, including hair follicles where it modifies hair shaft proteins.\textsuperscript{28,29} Although the enzyme has already been a focus of interest in hair biology, it could not be linked to any disorder until now. \textit{TGM3} encodes transglutaminase 3, a member of the transglutaminase family (EC.2.3.2.13), which catalyzes the calcium-dependent formation of isopeptide bonds between glutamine and lysine residues in various proteins including the archetypal hair shaft protein trichohyalin, encoded by \textit{TCHH}. 
TCHH is a structural protein located and co-expressed localized with PADI3 in the inner root sheath of the hair follicle and in the medulla of the hair shaft. Deimination by PADI3 reduces the overall charge of TCHH, and that enables its association with the keratin intermediate filaments (KIF). Then, TCHH and KIF are crosslinked together by TGM3. KIFs are then stabilized, hardened and linked to cornified envelopes through further crosslinking by transglutaminases, particularly by TGM3 (Figure 2H).\(^{30-32}\) Thereby, TCHH and its sequential modifications by PADI3 and TGM3 have a very important role in shaping and mechanical strengthening of the hair. Of note, the TCHH mutation we identified leads to the synthesis, if any, of a very short protein, probably without any function in KIF interaction as the KIF interacting domain would be almost entirely missing (Figure 2G).

**Missense mutations in PADI3 affect the 3-D enzyme structure**

We next investigated the consequences of PADI3 mutations on the corresponding proteins. The p.Lys578* is expected to induce the synthesis of a truncated protein lacking the 87 amino acids of the carboxy terminal, in particular the Cys646 (Figure 2C, Table S6) absolutely necessary for the enzyme activity.\(^{28}\) Intriguingly, we observed that the three PADI3 amino acids substituted as a result of the missense mutations correspond to residues that are conserved in the five human PADI proteins, and also in the PADI3 from other species, suggesting they have an important role (Figure S3). However, none of them is directly involved in the catalytic site or in one of the five calcium-binding sites of PADI3 (Table S6). Nevertheless, when we analyzed the effect of the PADI3 missense mutations on the predicted three-dimensional structure of the enzyme,\(^{15}\) the mutations p.Ala294Val and p.Pro605Thr were shown to induce clear modifications of beta-sheets and alpha-helices, in particular in the immunoglobulin-like NH2 domains, and also around the catalytic site and the calcium-binding sites. The effects of the p.Leu112His
substitution were less drastic (Figure 3 and Figures S4, S5).

**Aggregation and reduced enzymatic activity of PADI3 mutants**

We then cloned the wild-type WT *PADI3* cDNA into a mammalian expression vector in order to express-induce the translation of a C-terminally V5-tagged PADI3 protein. Mutant constructs with the three recurrent missense mutations were generated by targeted mutagenesis. HaCaT cells were transiently transfected (5-10% transfection efficiency) with constructs encoding for WT and mutant forms of PADI3—were everexpressed in the transiently transfected HaCaT human keratinocyte cell line (5-10% transfection efficiency). Immunoblotting of cell extracts showed that all of the constructs led to the WT and mutated PADI3 constructs led to expression-translation of a protein of about 70 kDa (Figure 4A). The subcellular location of WT and mutated proteins was determined by immunofluorescence analyses that showed, as expected, a diffuse homogenous cytoplasmic distribution of the WT PADI3, whereas in all three mutants the proteins were observed to form large aggregates throughout the cytoplasm (Figure 4B). To assess the enzymatic activity of WT and mutated PADI3, we performed double immunostaining with an anti-V5 monoclonal antibody and with human anti-citrullinated protein autoantibodies (ACPA) from individuals with rheumatoid arthritis—patients, these antibodies specifically detecting citrullinated proteins. While overexpression-translation of the WT PADI3 resulted in a strong labeling with the ACPA antibodies, the signal in the cells expressing producing the mutant proteins was barely above background (Figure 5A). We also produced the WT and mutant PADI3 in *E. coli*. After incubation of the WT PADI3-containing bacterial extracts with calcium for two hours, deiminated proteins were detected. By contrast, when the extracts containing the mutated PADI3 were incubated for two hours, and even up to eighteen hours, no deiminated proteins were detected (Figure 5B and Figure S6). Altogether, the results suggested that the
mutated forms of PADI3 are either not or only weakly active.

**Padi3 knockout mice show whisker and hair anomalies**

In order to demonstrate the importance of PADI3 in hair shaft formation and structure, we generated *Padi3* knockout mice (Figure 6A-B). Breeding mice heterozygous for the *Padi3*™1a mutation produced offspring with the three possible genotypes at the expected Mendelian ratios, showing that absence of Padi3 is compatible with life. Grossly, the skin of 7-weeks old null mice appeared normal. A further characterization by SEM revealed alterations in the morphology of hair coat (Figure 6C) and, less markedly, of whiskers. The surface of the lower (proximal) part of the vibrissae and the hairs on their entire length were irregular and rough and appeared as hammered.

**Nonsense mutation in TGM3 leads to reduced enzymatic activity**

We cloned the WT *TGM3* cDNA into a mammalian expression vector in order to express induce the translation of an N-terminally FLAG-tagged TGM3 protein. Mutant construct was generated by targeted mutagenesis. WT and mutant TGM3 were overexpressed in the transiently transfected HaCaT and HEK293T cell lines were transiently transfected with WT and mutant TGM3 encoding constructs. WT TGM3 construct produced led to translation of a protein of about 70 kDa, while the mutated construct nonsense mutation resulted in a truncated protein of around 40 kDa with a lower detection level (Figure 7A and Figure S7). Immunofluorescence analysis showed that TGM3 is located in the cytoplasm and that the truncated form is present in a dramatically lower number of cells (Figure 7B) in accordance with the western blot results. Generally these cells had a smaller cytosolic surface area in comparison to those overexpressing producing the WT TGM3 (Figure 7B). We performed a transglutaminase activity assay23 with HEK293T cell lysates overexpressing containing WT and mutated TGM3. The analysis results revealed that the WT had a
significantly higher transglutaminase activity in comparison to the truncated protein and the latter did not differ from the mock transfected negative control (Figure 7C and Figure S8).

Discussion

In this study we identified disease causative mutations for UHS in PADI3, TGM3 and TCHH with the former two genes encoding for posttranslational modification enzymes that act on the structural hair protein trichohyalin encoded by the latter gene. Our cell culture data show that the identified mutations in PADI3 and TGM3 lead to reduced or no enzymatic activity and the phenotype of the Padi3 knockout mice we generated show structural alterations in the whiskers and hair coat morphology. Our findings are also supported by the phenotype of the already existing Tgm3 knockout mice. These mice exhibit irregular, twisted whiskers and, at birth, have a wavy hair coat, which improves four weeks after birth. Scanning and transmission electron microscopy analyses of hairs from adult Tgm3−/− mice reveal alterations such as irregular torsions, deformed grooves, abnormal cuticle and shorter KIF. It is also convincing that, both nonsense and missense mutations in the Tgm3 gene are responsible for the wellhaarig mouse phenotype, named for the curly whiskers and wavy coat of the mutant animals. Based on the phenotype of the Tgm3−/− mice, John et al. have suggested that alterations in TGM3 or its substrates could be related to recessive forms of pili torti [MIM 261900] or similar hair phenotypes, which improve with age. Our findings validate this hypothesis and furthermore identify UHS as the hair phenotype related to alterations not only in TGM3 but also in the other proteins of the TCHH-PADI3-TGM3 interplay cascade. In some affected individuals, TCHH would not be produced, or produced as a truncated form unable to interact with KIF; in others, because of a PADI3 activity defect, TCHH would remain insoluble preventing its
interaction with KIF; in the last group, TCHH/KIF interaction would not be stabilized by TGM3-mediated crosslinks. Taken together, this suggests that one of the particular processes in hair shaft formation that leads to UHS when disturbed might be the interaction of TCHH and KIF. This interaction is known to be crucial for shaping and mechanical strengthening of the hair shaft. These findings also show that the compromise of any one of the proteins that play a role in this process would be enough to lead to the same phenotype.

It is intriguing that, despite the defects affecting a structural component of the hair shaft, the phenotype in UHS is commonly reported to improve with age, similar to the hair coat phenotype of Tgm3-/− mice. Interestingly, improvement with age has also been observed in other hair shaft disorders (e.g. pili annulati, pili torti). The improvement in UHS might be due to the compensatory expression of another isoform of peptidylarginine deiminase, transglutaminase or other structural hair shaft components. On the other hand, aging related changes in hair follicles such as increase in diameter and length can have mechanistic influences that might account for this improvement.

TGM3 and PADI3 are strongly detected in the upper epidermis. Nevertheless, no anomalies have been reported in the interfollicular epidermis of individuals with isolated UHS. Similarly, Tgm3-/− mice show no obvious skin defects. This is probably due to the fact that other isoforms of these enzyme families are present in the epidermis, which can compensate for the loss of PADI3 and TGM3 activity, whereas these two are the only isoforms detected in the hair cuticles and medulla.

Up to now, both sporadic-simplex and familial cases of UHS have been reported with suggested autosomal dominant and recessive inheritance with variable levels of penetrance. In this study we consistently observed an autosomal recessive
inheritance pattern in a total of 11 familial and sporadic simplex cases. Based on the pedigrees reported in literature, it is most likely that autosomal dominant forms of this condition exist\(^7; \)\(^{36}; \)\(^{37}\) which might be underlined by defects in other genes involved in hair shaft formation and maintenance related processes. It would be of interest then to investigate closely whether differences could be observed in the phenotypes of these individuals in comparison to the individuals who carry recessive mutations in PADI3-TCHH-TGM3 interplay. An interesting observation was that, 5 out of 60,659 individuals in ExAC are homozygous for c.881C>T (p.Ala294Val). UHS is a non-debilitating phenotype that resolves with age and therefore, it is likely that these presumably affected individuals had participated in the ExAC project as "healthy" controls. This data also indicates that UHS is a more common phenotype than estimated. In summary, we elucidated the molecular genetic background of UHS by identifying recessive mutations in PADI3, TCHH and TGM3. The three genes encode for proteins that play an essential role during hair shaft formation through their sequential interactions. This finding, in combination with the data describing the functional effects of the mutations in PADI3 and TGM3, provides valuable information regarding the pathophysiology of UHS. Furthermore, it contributes to a better understanding of the protein interaction cascades in molecular histogenesis of the hair. This could be of further value for cosmetics and pharmaceutics industries paving the way for development of novel products.

**Conflict of Interest Statement**

P.N. is a founder, CEO, and shareholder of ATLAS Biolabs GmbH. ATLAS Biolabs GmbH is a service provider for genomic analyses. All other authors declare that they...
have no conflict of interest.

Supplemental Data

Supplemental data include 9 figures and 6 tables.

Acknowledgments

P.N. is a founder, CEO, and shareholder of ATLAS Biolabs GmbH. ATLAS Biolabs GmbH is a service provider for genomic analyses. All other authors declare that they have no conflict of interest.

We would like to thank the individuals and their families for participating in this study. We would like to acknowledge Dr Marianne Chabod, the technical assistance of Carole Pons and Géraldine Offer, the Toulouse Rio Imagerie imaging (INSERM U1043) and electron microscopy (University of Toulouse) facilities, and the TAMM animal facility, in particular Laëtitia Trottereau. We would like to thank Dr. Thomas Zillinger for providing us with HEK293T cells. We would like to acknowledge Dr. Thomas Butterbrodt from Bio-Rad Laboratories GmbH and Dr. Kourosh Zolghadr from Leica Biosystems for their technical assistance. S.S. is supported by the Deutsche Forschungsgemeinschaft (DFG, SFB1089), the German Ministry of Research and Education (BMBF, 01GQ0806), and the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602102 (EPITARGET). V.O is supported by the German Research Foundation (DFG) (OJ 53/3-1). M.S. and G.S. are supported by The University of Toulouse, the Centre National de la Recherche Scientifique and the Institut National de la Santé et de la Recherche Médicale. This work was further supported by local funding (BONFOR to R.C.B. and S.S.). R.C.B. is a member of the DFG-funded Excellence Cluster ImmunoSensation and was a recipient of a Heisenberg Professorship of the DFG (BE
518  2346/4-2).

§19
Web Resources

https://varbank.ccg.uni-koeln.de/


USCS Genome Bioinformatics website: http://genome.ucsc.edu/cgi-bin/hgGateway

Exome Aggregation Consortium (ExAC) database (accessed 5 March 2015),

http://exac.broadinstitute.org/

http://www.mousephenotype.org/data/search/gene?kw=padi3


17. Posch, A., Kohn, J., Oh, K., Hammond, M., and Liu, N. (2013). V3 stain-free workflow for a practical, convenient, and reliable total protein loading control in...


31. Tarcsa, E., Marekov, L.N., Andreoli, J., Idler, W.W., Candi, E., Chung, S.I., and


Figure Legends

Figure 1. Clinical appearance of UHS

(A-G) Clinical presentation of UHS. Typical signs of UHS can be observed in (A-C) three German girls, (D) a German boy, (E) a Swiss boy, and (F-G) a Danish girl, who were included in the study. (G) The improvement of the phenotype with aging can be observed in the Danish girl. (H) SEM image of the Danish girl’s hair shaft showing the longitudinal groove (I) in comparison to a normal hair shaft. (J) The improved hair phenotype at age 15 and (K-L) the SEM findings of the male sibling from the UK family. (K) Longitudinal grooves and (I) heart-shaped cross section of hair presented (M) in comparison to the circular cross section from a control hair shaft, are indicative of UHS. Detailed information regarding the clinical histories can be found in the Supplemental Note; Case Reports.
Figure 2. Mutations causing UHS and interplay of PADI3, TGM3 and TCHH

(A) The homozygous c.881C>T (p.Ala294Val) mutation in PADI3 identified by exome sequencing in the UK siblings was verified by Sanger sequencing. The mutation cosegregates with the UHS phenotype in the pedigree as shown in Figure S1. (B) Electropherograms show the PADI3 mutations c.335T>A (p.Leu112His), c.1813C>A (p.Pro605Thr) and c.1732A>T (p.Lys578*) in comparison to the wild type sequences. (C) Schematic representation of PADI3 showing the various domains of the protein, the positions of calcium-binding sites (*), and of major amino acids involved in the catalytic sites (v). The positions of the substitutions responsible for UHS are indicated by an arrow. (D) Electropherograms show the homozygous TGM3 mutation c.1351C>T (p.Gln451*) identified in the Turkish male in comparison to the wild type sequence. (E) Schematic representation of TGM3. (F) Electropherograms show the homozygous TCHH mutation c.991C>T (p.Gln331*) identified in the German female in comparison to the wild type sequence. (G) Schematic representation of TCHH. (H) Cartoon depicting the cascade of interactions between TCHH, PADI3 and TGM3 in hair shaft biology. In trichohyalin granules (grey areas), TCHH appears as a dimer with a long rod-shaped domain and a globular end domain. After deimination by PADI3, TCHH is less structured, and the granules progressively dissolved. Citrullinated-TCHH (TCHH-Cit) interacts with keratin intermediate filaments (black lines) organizing them, and becomes a substrate for TGM3. Cross-links of TCHH to itself (intra- or inter-chains), to keratins and between keratins and the cornified cell envelope components are then catalyzed (green dash).
Figure 3. Topological tridimensional models of WT and mutant PADI3

(A) Overall view of the tridimensional solid-ribbon representation of calcium-bound WT and three mutant PADI3 models. The tridimensional solid residues Leu112, Ala294 and Pro605, with their respective lateral chains, are reported on the proposed model of the WT enzyme, as well as the corresponding substituted amino acids on the model of each mutant, p.Leu112His, p.Ala294Val and p.Pro605Thr. The four amino acids involved in the catalytic site are also shown. According to these models, the p.Ala294Val and p.Pro605Thr substitutions induce a profound disorganization of the predicted immunoglobulin-like domains, with disappearance of several beta-sheets, and modification of some alpha-helices of the catalytic domain, as compared to the WT. The effect of the p.Leu112His substitution is more discrete. (B) Zoom on the major amino acids involved in the catalytic site. Its proposed structure is clearly modified after p.Ala294Val and p.Pro605Thr substitutions. It should be noted that none of the substituted amino acids are directly involved in this site.
Figure 4. Overexpression of WT and mutant forms of PADI3 produced in HaCaT cell line.

(A) Immunoblotting analysis shows the expression–translation of WT and mutant PADI3 in transiently transfected HaCaT cells, which were collected 48 h post-transfection. Immunoblotting was performed with anti-V5 and anti-PADI3 antibodies. Antibody-specific bands are indicated with an arrow and a non-specific cross-reactive band around 55 kDa is indicated with an asterisk. Full length blot images can be seen in Figure S9. (B) Immunofluorescence analysis in HaCaT cells transiently expressing transfected with WT and mutant PADI3 encoding plasmids shows the homogeneous cytosolic expression–localization of WT PADI3 whereas the three mutant proteins are observed in the form of large aggregates. Scale bars, 10µm.
Figure 5. Consequences of PADI3 mutations on the enzyme activity.

(A) Indirect immunofluorescence analysis of transfected HaCaT cells. HaCaT cells were double labeled with anti-V5 monoclonal antibody (green) and ACPA antibodies (red). Nuclei were labeled with DAPI (blue). Scale bars, 10 µm. The overexpressed WT PADI3 is clearly active (merge image; yellow color) whereas the mutants display a low activity. (B) WT PADI3 (bacterial clones 1 and 2) and the mutant forms, p.Leu112His (clones 7 and 8), p.Ala294Val (clones 11 and 12) and p.Pro605Thr (clones 14 and 15), expressed in E. coli, were extracted in Tris-HCl buffered salt. Soluble proteins were incubated for the indicated period of time (t; in hours) with calcium, separated by electrophoresis, transferred to membranes, stained with Ponceau Red and immunodetected with either the anti-modified citrulline rabbit antibodies or anti-V5 antibody. While citrullinated proteins were detected when the WT-containing extracts have been incubated for two hours, no citrullinated proteins were detected in the mutant-containing extracts, even after 18 hours of incubation. The substituted enzymes appear to be cleaved and a V5-reactive doublet is observed. Molecular mass markers are indicated on the right in kDa. Full length blot images can be seen in Figure S9.
Figure 6. *Padi3* gene disruption in mice.

(A) Schematic representation of the *Padi3* gene and the targeting vector. The exons are shown by numbered grey rectangles. A cassette containing the beta-galactosidase (LacZ) and neomycin (neo) genes is inserted between exons 4 and 5. This results in the production of a truncated Padi3 protein corresponding to amino acids 1-136 fused to β-galactosidase. The position of the inserted loxP and flippase recognition target (FRT) sites are indicated, as well as the splicing acceptor site (SA) and the polyadenylation sites (pA) of LacZ and neo. The positions of the oligonucleotides (dashes) used for genotyping are shown, as well as the length of the amplified PCR products in wildtype (Padi3wt) and targeted (Padi3tm1a) alleles. (B) PCR on genomic DNA from tail biopsies of 10 mice from the same littermate (five females, 1-5, and five males, 6-10) showing amplification of the 241 bp fragment for the Padi3wt allele and the 365 bp fragment for the Padi3tm1a allele. (C) Representative pictures of SEM analysis of back hair coat from the three wt and three Padi3tm1a/tm1a mice (7 weeks old). Most hairs of the knockout mice are rough, with an irregular surface (white arrows). *This is evident for thick hairs (top and middle micrographs), but was also observed for thin hairs (bottom). In some cases the hairs are twisted. The boxed areas are enlarged in the middle, in some cases they are twisted. The boxed areas are enlarged on the bottom.* At least six vibrissae and 200 hairs were analyzed per animal. Scale bar = 50 µm.
Figure 7. **Overexpression of WT and mutant forms of TGM3 produced in HaCaT and HEK293T cell lines**

**(A)** Immunoblotting analysis shows the expression—translation of WT and truncated TGM3 in transiently transfected HaCaT cells, collected 48 h post-transfection. Immunoblotting was performed with anti-Flag and anti-TGM3 antibodies. Antibody-specific bands showing the WT (~70 kDa) and truncated TGM3 (~40 kDa) are indicated with an arrow and a non-specific cross-reactive band around 55 kDa is indicated with an asterisk. The truncated TGM3 can only be detected with the antibody against the Flag epitope fused to the N-terminus and not with the antibody against the C-terminus of TGM3 as expected. Full length blot images can be seen in Figure S9. Immunoblotting analysis with HEK293T cells is presented in Figure S7.

**(B)** Immunofluorescence analyses in HaCaT and HEK293T cells transiently expressing—transfected with WT and mutant TGM3 encoding constructs are presented by images captured with 10x and 63x objectives. The analyses show clear differences in the number of cells expressing—producing the WT and mutant TGM3 (10x images). Scale bars, 50 µm and 10 µm for 10x and 63x objectives, respectively.

**(C)** Transglutaminase activity of WT and mutated TGM3 overexpressed—produced in HEK293T cells. Mock transfected cell lysates were used as negative control. The transglutaminase activity, represented by the mean slope of 10-minute long measurements from technical triplicates (given in Figure S8), is presented as a dot plot. The enzymatic activity assay was performed with samples emerging from five independent transfections. Horizontal lines represent the mean values (mean ± SD; WT: 0.84±0.45; p.Gln451*: 0.10±0.04; mock: 0.07±0.02). Results demonstrate that the mutated protein did not differ from the mock transfected negative control in terms of activity and WT TGM3 had a significantly higher activity in comparison to both (*P<0.05, Dunn’s Test).
<table>
<thead>
<tr>
<th>Country</th>
<th>Gene</th>
<th>Mutation</th>
<th>Consequence</th>
<th>Clinical description</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Kingdom</td>
<td>PADI3</td>
<td>c.881C&gt;T, homozygous</td>
<td>p.Ala294Val</td>
<td>This study</td>
</tr>
<tr>
<td>Denmark</td>
<td>PADI3</td>
<td>c.881C&gt;T, homozygous</td>
<td>p.Ala294Val</td>
<td>Nissen and Svendsen 2013</td>
</tr>
<tr>
<td>Germany</td>
<td>PADI3</td>
<td>c.335T&gt;A, homozygous</td>
<td>p.Leu112His</td>
<td>This study</td>
</tr>
<tr>
<td>Germany</td>
<td>PADI3</td>
<td>c.881C&gt;T, c.335T&gt;A</td>
<td>p.Ala294Val, p.Leu112His</td>
<td>This study</td>
</tr>
<tr>
<td>Germany</td>
<td>PADI3</td>
<td>c.881C&gt;T, c.335T&gt;A</td>
<td>p.Ala294Val, p.Leu112His</td>
<td>This study</td>
</tr>
<tr>
<td>Germany</td>
<td>PADI3</td>
<td>c.881C&gt;T, c.1813C&gt;A</td>
<td>p.Ala294Val, p.Pro605Thr</td>
<td>This study</td>
</tr>
<tr>
<td>Germany</td>
<td>PADI3</td>
<td>c.335T&gt;A, c.1813C&gt;A</td>
<td>p.Leu112His, p.Pro605Thr</td>
<td>This study</td>
</tr>
<tr>
<td>Switzerland</td>
<td>PADI3</td>
<td>c.881C&gt;T, c.1732A&gt;T</td>
<td>p.Ala294Val, p.Lys578*</td>
<td>This study</td>
</tr>
<tr>
<td>Turkey</td>
<td>TGM3</td>
<td>c.1351C&gt;T, homozygous</td>
<td>p.Gln451*</td>
<td>Kilic et al. 2013</td>
</tr>
<tr>
<td>Germany</td>
<td>TCHH</td>
<td>c.991C&gt;T, homozygous</td>
<td>p.Gln331*</td>
<td>This study</td>
</tr>
</tbody>
</table>
Click here to access/download
**Supplemental Text and Figures**
Basmanav et al_Supplemental_AJHG.pdf
Patient Consent for Medical Photography

Patient name: Sophia Gruber  Date: 4.10.15

☐ check here if minor or unable to provide consent

I consent for medical photographs to be made of me or my child (or person for whom I am legal guardian). I understand that the information may be used in my medical record, for purposes of medical teaching, or for publication in medical textbooks or journals as I have designated below. By consenting to these medical photographs I understand that I will not receive payment from any party. Refusal to consent to photographs will in no way affect the medical care I will receive. If I have any questions or wish to withdraw my consent in the future I may contact:

By signing this form below I confirm that this consent form has been explained to me in terms which I understand.

1) I consent for these photographs to be used in medical publications, including medical journals, textbooks, and electronic publications. I understand that the image may be seen by members of the general public, in addition to scientists and medical researchers that regularly use these publications in their professional education. Although these photographs will be used without identifying information such as my name, I understand that it is possible that someone may recognize me. I also agree for my image to be shown for teaching purposes and to be used for my medical record.

__________________ (Signature) __________________ (Witness)

2) I agree for my image to be shown for teaching purposes AND to be used for my medical record but NOT FOR medical publication:

__________________ (Signature) __________________ (Witness)

3) I agree to use of my image for medical records ONLY:

__________________ (Signature) __________________ (Witness)

For patients between ages 7 and 18 years, a signature below indicates that the information in this consent form has been explained to me, and I assent to use of my images as outlined above:

__________________ (Signature of patient) __________________ (Witness)
CONSENT TO PUBLICATION OF MATERIAL ABOUT THE PATIENT

PLEASE USE BLOCK CAPITALS

Patient name: Kristina Cooper

I hereby confirm that I give consent for my photograph to be published.

It has been explained to me that the material has educational value. I therefore consent to the material being shown to appropriate professional staff (i.e. health care professionals, including students) and published in educational publications, journals, textbooks in any form or medium (including all forms of electronic publication or distribution). I also understand that it is possible that the material may be seen by the general public. Although these photographs will be used without any identifying information such as my name, I understand that full anonymity cannot be guaranteed and that it is possible that someone may recognize me.

I understand that upon transmission of this form to a scientific journal my identity (but not my medical records) will be divulged to the editorial office of the journal.

I understand that I may view the material by arrangement with .................................................. I understand that no fee is payable by .................................................. or any other person for use of the material either now, or at any time in the future.

I confirm that the purpose for which the material may be used has been explained to me in terms which I have understood. It has been made clear to me that refusal to consent will in no way affect my medical care. I confirm that I am over 18 years old, of sound mind and that I am not signing under any form of duress.

To be completed by the patient or parent/guardian, or next of kin if the patient is under 18 years of age, or deemed unfit to give legal consent.

Full name: .................................................................

Address: ........................................................................

Signature ................................................................. Date: ........................................

(Patient, parent/guardian or next of kin)

Signature................................................................. Date: ........................................

Hospital details

Date: .........................................................................

This form is largely based on the consent form of Oxford Medical Illustration, John Radcliffe Hospital, Oxford and their kind permission in making their consent form available is gratefully acknowledged.
CONSENT TO PUBLICATION OF MATERIAL ABOUT THE PATIENT

PLEASE USE BLOCK CAPITALS

Patient name: Samira Eilers

PATIENT CONSENT

I hereby confirm that I give consent for my photograph to be published.

It has been explained to me that the material has educational value. I therefore consent to the material being shown to appropriate professional staff (i.e., health care professionals, including students) and published in educational publications, journals, textbooks in any form or medium (including all forms of electronic publication or distribution). I also understand that it is possible that the material may be seen by the general public. Although these photographs will be used without any identifying information such as my name, I understand that full anonymity cannot be guaranteed and that it is possible that someone may recognize me.

I understand that upon transmission of this form to a scientific journal my identity (but not my medical records) will be divulged to the editorial office of the journal.

I understand that I may view the material by arrangement with Dr. K. Garcia-Belts. I understand that no fee is payable by me or any other person for use of the material either now, or at any time in the future.

I confirm that the purpose for which the material may be used has been explained to me in terms which I have understood. It has been made clear to me that refusal to consent will in no way affect my medical care. I confirm that I am over 18 years old, of sound mind and that I am not signing under any form of duress.

To be completed by the patient or parent/guardian, or next of kin if the patient is under 18 years of age, or deemed unfit to give legal consent.

Full name: Eilers, Samira Katharina Eboline Aliwine

Address: Potsdamweg 50, 12643 Berlin

Signature: [Signature]
Date: 13.09.15

(Patient, parent/guardian or next of kin)

Signature: [Signature]
Date: 13.09.15

Hospital details

Date: [Date]

This form is largely based on the consent form of Oxford Medical Illustration, John Radcliffe Hospital, Oxford and their kind permission in making their consent form available is gratefully acknowledged.
CONSENT TO PUBLICATION OF MATERIAL ABOUT THE PATIENT

PLEASE USE BLOCK CAPITALS

Patient name: .................................................................

PATIENT CONSENT

I hereby confirm that I give consent for my photograph to be published.

It has been explained to me that the material has educational value. I therefore consent to the material being shown to appropriate professional staff (i.e. healthcare professionals, including students) and published in educational publications, journals, textbooks in any form or medium (including all forms of electronic publication or distribution). I also understand that it is possible that the material may be seen by the general public. Although these photographs will be used without any identifying information such as my name, I understand that full anonymity cannot be guaranteed and that it is possible that someone may recognize me.

I understand that upon transmission of this form to a scientific journal my identity (but not my medical records) will be divulged to the editorial office of the journal.

I understand that I may view the material by arrangement with ......................... I understand that no fee is payable by ......................... or any other person for use of the material either now, or at any time in the future.

I confirm that the purpose for which the material may be used has been explained to me in terms which I have understood. It has been made clear to me that refusal to consent will in no way affect my medical care. I confirm that I am over 18 years old, of sound mind and that I am not signing under any form of duress.

To be completed by the patient or parent/guardian, or next of kin if the patient is under 18 years of age, or deemed unfit to give legal consent.

| Full name: ................................................................. |
| Address: ........................................................................|
| Signature ........................................................ Date: ___________________________ |
| (Patient, parent/guardian or next of kin) |

Signature. ........................ Date 8/9 -15

Hospital details: Odense University Hospital

Date: 08.09.2015

This form is largely based on the consent form of Oxford Medical Illustration, John Radcliffe Hospital, Oxford and their kind permission in making their consent form available is gratefully acknowledged.